JP 4.01 Bacterial Endotoxins Test

The BET detects or quantifies endotoxins from Gram-negative bacteria in parenteral pharmaceuticals and other materials where endotoxin control is required. The compendial methods use Limulus amebocyte lysate (LAL); results are compared to a product-specific endotoxin limit calculated from dose and route. JP 4.01 is harmonized with USP <85> and Ph. Eur. 2.6.14 under ICH Q4B Annex 14, provided the chapter is followed in full, without mixing procedures from other pharmacopoeias.

The LAL coagulation cascade is activated by endotoxin. The test measures this reaction to determine presence or concentration.

• Method A: Gel-clot — qualitative/semi-quantitative limit test (formation of a firm clot).

• Method B (Turbidimetric, endpoint or kinetic) photometric detection of increasing turbidity proportional to endotoxin.

• Method C: Chromogenic (kinetic or endpoint) — photometric detection of a chromophore released in the cascade.

• JP recognizes recombinant protein–based endotoxin assays (e.g., rFC or recombinant cascade reagents) in a General Information chapter that provides procedures and considerations for their use as alternatives to LAL, separate from JP 4.01. these recombinant methods are referenced outside JP 4.01 (in a General Information chapter), so they are not yet formally interchangeable with LAL in compendial testing.
• EP includes rFC in 2.6.32; USP has pursued a recombinant chapter via the Pharmacopeial Forum process.